WaveMan
WaveMan · Company
SINT · Sintx Technologies, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

SINT Sintx Technologies (SINT) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001269026
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
7
13F, latest reported quarter

Sintx Technologies insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Sintx Technologies, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Lyons Christopher Michael
Director
BUY
2026-03-10 SECtraded 2026-03-02
7,534
$21.8K
-46.1%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Feb 25, 2026.
  • The trade is 90.9% of the 8,292 shares held after it.
  • 2 other insiders bought within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lyons Christopher Michael bought about $21.8K of SINT on Mar 2, 2026; 2 other insiders bought within 30 days and 7 funds added in the latest 13F quarter.
Lyons Christopher Michael
Director
BUY
2026-03-10 SECtraded 2026-02-25
758
$2.2K
-46.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 758 shares held after it.
  • 2 other insiders bought within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lyons Christopher Michael bought about $2.2K of SINT on Feb 25, 2026; 2 other insiders bought within 30 days and 7 funds added in the latest 13F quarter.
MOYES JAY M
Director
BUY
2026-02-25 SECtraded 2026-02-23
1,000
$2.9K
-46.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 26, 2025.
  • The trade is 25.0% of the 4,000 shares held after it.
  • 2 other insiders bought within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MOYES JAY M bought about $2.9K of SINT on Feb 23, 2026; 2 other insiders bought within 30 days and 7 funds added in the latest 13F quarter.
Anderson Mark Lewis
Director
BUY
2026-02-19 SECtraded 2026-02-18
3,000
$9.1K
-48.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jun 18, 2025.
  • +11.7% median (+11.7% mean) 90-day return after 2 previous buys.
  • The trade is 16.7% of the 18,000 shares held after it.
  • 2 other insiders bought within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Anderson Mark Lewis bought about $9.1K of SINT on Feb 18, 2026; 2 other insiders bought within 30 days and 7 funds added in the latest 13F quarter.
Honigblum Gregg R.
Chief Investment Officer
BUY
2025-12-09 SECtraded 2025-12-08
5,000
$21.2K
-61.4%
Context
  • 25 earlier Form 4 trades (code P or S) here by this insider (25 buys), the last on Dec 5, 2025.
  • -9.1% median (+2.3% mean) 90-day return after 4 previous buys.
  • The trade is 2.5% of the 201,067 shares held after it.
  • No other insider bought within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Investment Officer Honigblum Gregg R. bought about $21.2K of SINT on Dec 8, 2025; 7 funds added in the latest 13F quarter.
45 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 40 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
7 funds bought in last quarter
below 92% of Medical Devices
Revenue
-64.7% year over year
below 95% of Medical Devices
Margin
-1018.1% net margin
below 98% of Medical Devices
Buybacks
$133.0K repurchased, FY to 2025-12-31
below 97% of Medical Devices
Short interest
1.8% of the float short (float per yahoo 2026-10-26) · 2.1 days to cover · settled 2026-09-30
below 69% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch SINT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-54.9%12M
-60%-32%-4%+23%2025-102025-122026-022026-042026-062026-082026-10 2026-03-02 · Lyons Christopher Michael bought $21.8K2025-12-08 · Honigblum Gregg R. bought $21.2K2025-12-05 · Honigblum Gregg R. bought $20.4K2025-12-05 · Honigblum Gregg R. bought $20.1K2025-12-05 · Honigblum Gregg R. bought $20.0K2025-12-05 · Honigblum Gregg R. bought $19.8K2025-12-05 · Honigblum Gregg R. bought $19.7K2025-12-05 · Honigblum Gregg R. bought $19.6K2025-12-05 · Honigblum Gregg R. bought $19.4K2025-12-05 · Honigblum Gregg R. bought $19.3K2025-12-05 · Honigblum Gregg R. bought $18.9K2025-11-07 · Honigblum Gregg R. bought $16.0K2025-11-07 · Honigblum Gregg R. bought $15.9K2025-12-08 · Honigblum Gregg R. bought $13.7K2026-02-18 · Anderson Mark Lewis bought $9.1K2026-02-23 · MOYES JAY M bought $2.9K2026-02-25 · Lyons Christopher Michael bought $2.2K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SINT: institutional holders (13F)

13F holdings, latest reported quarter
Bleichroeder LP
523,013 sh
$978.0K
Stonepine Capital Management, LLC
836,820 sh
$891.0K
Veracity Capital LLC
76,674 sh
$143.4K
CITADEL ADVISORS LLC
31,930 sh
$59.7K
GEODE CAPITAL MANAGEMENT, LLC
30,101 sh
$56.3K

Congress trades in SINT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SINT planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

SINT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$42.2K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$39.1K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$9.6K position · as of 2026-05-31
0.0%
Dimensional U.S. Core Equity 2 ETF
$2.3K position · as of 2026-07-31
0.0%
Fidelity Total Market Index Fund
$4.2K position · as of 2026-05-31
0.0%
Blackstone Alternative Multi-Strategy Fund
$80 position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · B. Sonny Bal
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$440.7K
$411.3K
$369.8K
n/a
n/a
2023
$537.3K
$461.7K
$453.6K
n/a
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. This filer reported no return figures.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 7 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

SINT financials

Revenue growth
-64.7%
XBRL, annual
Net margin
-1018.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.3M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-848.2%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$10.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.02x
long-term 2023-06-30 (36 months older than the period end) plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
-87.99x
TTM operating cash flow over long-term 2023-06-30 (36 months older than the period end) plus current 2026-06-30
Return on equity
-255.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-115.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-162.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$6.9M
market value at close 2026-10-26 on 2026-08-05 shares, plus long-term 2023-06-30 (36 months older than the period end) plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-99.4%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$1.0M$2.9M$2.6M$1.6M
Gross profit$461.0K$2.1M$1.8M$1.3M
Operating income-$10.7M-$14.0M-$13.4M-$11.3M
Net income-$10.4M-$11.0M-$8.3M-$12.0M
EPS (diluted)-6.16-15.19-624.47-60.81
Operating cash flow-$8.6M-$8.6M-$14.1M-$10.3M
Cash$4.1M$3.6M$3.3M$6.2M
Long-term debtn/an/an/a$368.0K
Buybacks$133.0Kn/an/an/a
SEC XBRL, fiscal years, as known on 2026-10-28

SINT Stock Sonar score 5/7 axes

Find similar shapesCompare

SINT ranks highest on financial health (41st percentile) and risk and compliance (39th), and lowest on growth (5th), among Medical Devices peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
12
Inputs
  • Return on equity-255.9% · 11 pct, sector of 183
  • Return on assets-115.0% · 15 pct, sector of 214
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-162.4% · 11 pct, sector of 188
Financial health
41
Inputs
  • Debt to equity0.02x · 80 pct, sector of 159
  • Cash flow to debt-87.99x · 1 pct, sector of 150
Growth
5
Inputs
  • Revenue growth, YoY-64.7% · 5 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
8
Inputs
  • Funds adding, latest quarter7 · 8 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
39
Inputs
  • Short interest, % of float+1.8% · 74 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+35.1% · 4 pct, sector of 198
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies